Stroke and other manifestations of brain schema are common and devastating disorders which dramatically deteriorate the patients quality of life and which in the EU produce annual costs of approximately 35 billions Euro. At the present no efficient therapy is available but there is increasing evidence that the outcome of alchemic injury is regulated by intrinsic genomic responses. To search for such genes, clinically relevant experimental brain schema models will be produced. Brain regions with reversible and irreversible injury will be identified and high throughput gene expression profiling will be carried out using Digital Expression Pattern Display *DEPD* and automated DNA chip technology. Outcome-specific genes will be identified and tested for path physiological relevance. Based on this information novel treatment strategies will be designed and evaluated forcherapeutical efficacy.
Funding SchemeCSC - Cost-sharing contracts
171 77 Stockholm
02 106 Warszawa
BD7 1DP Bradford